C
Claudia Cavelti-Weder
Researcher at University Hospital of Basel
Publications - 15
Citations - 515
Claudia Cavelti-Weder is an academic researcher from University Hospital of Basel. The author has contributed to research in topics: Diabetes mellitus & Medicine. The author has an hindex of 6, co-authored 9 publications receiving 428 citations.
Papers
More filters
Journal ArticleDOI
Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes
Claudia Cavelti-Weder,Andrea Babians-Brunner,Cornelia Keller,Marc A. Stahel,Malaika Kurz-Levin,Hany Zayed,Alan M. Solinger,Thomas Mandrup-Poulsen,Charles A. Dinarello,Marc Y. Donath +9 more
TL;DR: This novel IL-1β–neutralizing antibody improved glycemia, possibly via restored insulin production and action, and reduced inflammation in patients with type 2 diabetes.
Journal ArticleDOI
Identification of a SIRT1 Mutation in a Family with Type 1 Diabetes
Anna Biason-Lauber,Marianne Böni-Schnetzler,Basil P. Hubbard,Karim Bouzakri,Andrea Brunner,Claudia Cavelti-Weder,Cornelia Keller,Monika Meyer-Böni,Daniel T. Meier,Caroline Brorsson,Katharina Timper,Gil Leibowitz,Andrea Patrignani,Rémy Bruggmann,Gino Boily,Henryk Zulewski,Andreas Geier,Jennifer Cermak,Peter J. Elliott,James L. Ellis,Christoph H. Westphal,Urs Knobel,Jyrki J. Eloranta,Julie Kerr-Conte,François Pattou,Daniel Konrad,Christian M. Matter,Adriano Fontana,Gerhard Rogler,Ralph Schlapbach,Camille Regairaz,José M. Carballido,Benjamin Glaser,Michael W. McBurney,Flemming Pociot,David A. Sinclair,Marc Y. Donath +36 more
TL;DR: A family carrying a mutation in the SIRT1 gene, in which all five affected members developed an autoimmune disorder, is described, and a monogenic form of type 1 diabetes is unveiled.
Journal ArticleDOI
Development of an Interleukin-1β Vaccine in Patients with Type 2 Diabetes
Claudia Cavelti-Weder,Katharina Timper,Eleonora Seelig,Cornelia Keller,Martin Osranek,Ute Lässing,Gunther Spohn,Patrik Maurer,Philipp L. Müller,Gary T. Jennings,Joerg Willers,Philippe Saudan,Marc Y. Donath,Martin F. Bachmann +13 more
TL;DR: The vaccine hIL1bQb consisting of full-length, recombinant IL-1β coupled to virus-like particles was tested in a preclinical and clinical, randomized, placebo-controlled, double-blind study in patients with type 2 diabetes and was safe and well-tolerated.
Journal ArticleDOI
Inhibition of IL-1β Improves Fatigue in Type 2 Diabetes
Claudia Cavelti-Weder,Romana Furrer,Cornelia Keller,Andrea Babians-Brunner,Alan M. Solinger,Heidemarie Gast,Adriano Fontana,Marc Y. Donath,Iris K. Penner +8 more
TL;DR: It is hypothesized that fatigue levels may be increased in type 2 diabetes and may be improved by IL-1β antagonism, and within a placebo-controlled, double-blind study of IL- 1 β antagonism with a monoclonal anti–IL-1 β …
Journal ArticleDOI
Successful Use of Omalizumab in an Inadequately Controlled Type 2 Diabetic Patient With Severe Insulin Allergy
Claudia Cavelti-Weder,Bettina Muggli,Cornelia Keller,Andrea Babians-Brunner,Anna Biason-Lauber,Marc Y. Donath,Peter Schmid-Grendelmeier +6 more
TL;DR: A 62-year-old male patient with type 2 diabetes for 16 years developed a severe anaphylactic shock upon administration of intravenous, short-acting regular insulin, and genetic sequencing of the patient’s insulin molecule revealed a normal insulin gene.